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Polychlorinated biphenyls (PCBs) and poly-
brominated diphenyl ethers (PBDEs) are
halogenated chemicals that are persistent, have
potential for bioaccumulation, and can be
detected in most human and environmental
samples worldwide (Burreau et al. 2006;
Fonnum et al. 2006; Shen et al. 2006; Streets
et al. 2006). These two groups of organohalo-
gens are structurally related, but PCBs have
notably longer estimated half-lives in humans
than do PBDEs (Ogura 2004; Thuresson
et al. 2006). Commercial production of PCBs
began in the 1930s (International Programme
on Chemical Safety 1993) and most manufac-
turing, processing, and use of PCBs were
banned in the United States in the 1970s.
PBDEs were introduced commercially in the
1970s and have been in widespread use. Most
PBDEs have been banned in Europe and were
voluntarily withdrawn from the U.S. market
in 2004; DecaBDE is the exception and is still
in use in both Europe and North America
(Eriksson et al. 2001; U.S. Environmental
Protection Agency 2006). 
PCBs and PBDEs have structural similar-
ity to the thyroid hormone thyroxine (T4)
(Gill et al. 2004; Ulbrich and Stahlmann
2004). Prenatal exposure to PCBs and PBDEs
is of particular interest because these com-
pounds can cross the placenta and may inter-
fere with thyroid hormone production,
receptor binding, or transport, resulting in
altered hormone levels (Cheek et al. 1999;
Covaci et al. 2002; Mazdai et al. 2003).
Thyroid hormones are carefully regulated
in utero, and lower levels of T4 are associated
with impaired brain development (Howdeshell
2002; Porterﬁeld 2000; Winneke et al. 2002).
Some experimental studies conducted primar-
ily in mice and rats have found that prenatal
exposure to both PCBs and PBDEs may result
in decreased plasma total T4 (TT4) levels
and/or increased thyrotropin (TSH) (Brouwer
1989; Hallgren et al. 2001; Morse et al. 1996).
There is very little evidence relevant to the
impact of prenatal PBDE exposure on human
thyroid function, and studies examining the
impact of prenatal PCBs exposure have been
equivocal (Chevrier et al. 2007; Koopman-
Esseboom et al. 1994; Longnecker et al. 2000;
Pluim et al. 1992; Ribas-Fito et al. 2003;
Steuerwald et al. 2000; Wang et al. 2005). 
The objective of this study was to investi-
gate the relationship between serum cord
concentrations of PCBs and PBDEs and new-
born thyroid hormone function. Lipid-
adjusted cord serum concentrations of these
chemicals (nanograms per gram lipid) are rea-
sonable surrogates for fetal and maternal
exposure throughout pregnancy (Covaci et al.
2002; Mazdai et al. 2003). We hypothesized
that PCBs and PBDEs alter umbilical cord
blood thyroid hormone levels. Speciﬁcally, we
expected that PCB and PBDE levels would
be positively associated with TSH and nega-
tively associated with TT4 and free T4 (FT4).
Intrapartum stress associated with delivery
can substantially change thyroid hormone
levels (Copeland et al. 2002; Tehrani et al.
2003), potentially masking the effects of PCB
and PBDE body burdens. We assumed that
infants delivered with augmentation and/or
using nonelective cesarean sections generally
would have suffered more intrapartum stress
than those delivered by spontaneous unas-
sisted vaginal delivery (SUVD). To assess the
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BACKGROUND: Developing infants may be especially sensitive to hormone disruption from chemicals
including polychlorinated biphenyls (PCBs) and polybrominated diphenyl ethers (PBDEs).
OBJECTIVE: We investigated relationships between cord serum levels of PCBs and PBDEs and
thyroid hormones measured in cord blood serum and neonatal blood spots.
METHODS: We measured PCBs and PBDEs, thyrotropin (TSH), thyroxine (T4) and free T4 (FT4) in
cord blood serum from 297 infants who were delivered at the Johns Hopkins Hospital in 2004–2005.
We abstracted results of total T4 (TT4) measured in blood spots collected in the hospital and at
neonatal visits. We used delivery mode (augmented vaginal deliveries and nonelective cesarean deliver-
ies) as a surrogate for intrapartum stress, which is known to alter cord blood thyroid hormones. 
RESULTS: In the full study population, no compounds were associated with a change in average
TSH, FT4, or TT4. BDE-100 was associated with increased odds of low cord TT4, BDE-153 with
increased odds of low cord TT4 and FT4, and no compounds were associated with increased odds of
high TSH. For infants born by spontaneous, vaginal, unassisted deliveries, PCBs were associated
with lower cord TT4 and FT4 and lower TT4 measured in neonatal blood spots. PBDEs showed
consistent but mainly nonsigniﬁcant negative associations with TT4 and FT4 measurements.
CONCLUSIONS: Prenatal PCB and PBDE exposures were associated with reduced TT4 and FT4
levels among infants born by spontaneous, unassisted vaginal delivery. Intrapartum stress associated
with delivery mode may mask hormonal effects of PCBs and PBDEs.
KEY WORDS: children, cord blood, endocrine disruption, environmental health, polychlorinated
biphenyls, polybrominated diphenyl ethers, thyroid hormones. Environ Health Perspect
116:1376–1382 (2008). doi:10.1289/ehp.11379 available via http://dx.doi.org/ [Online 27 May
2008]possibility of later thyroid effects, we obtained
T4 data from blood spots collected at two
time points after delivery by the Maryland
neonatal screening program. 
Methods
Study design and population. Between
26 November 2004, and 16 March 2005, we
collected umbilical cord blood from women
delivering at the Johns Hopkins Hospital
(Apelberg et al. 2007; Herbstman et al. 2007).
All women with singleton deliveries were eligi-
ble for inclusion. We obtained approval from
the Maternal and Fetal Research Committee in
the Department of Gynecology and Obstetrics
and the Institutional Review Board at the
Johns Hopkins University School of Medicine.
This study required the collection of speci-
mens that otherwise would have been dis-
carded and information from medical records
that was available to hospital personnel.
Because we anonymized samples and data, the
study was exempted from requirements for
informed consent. The study received a
HIPAA (Health Insurance Portability and
Accountability Act) waiver. 
Over the course of the study period, 597
singleton births occurred at the Johns
Hopkins Hospital. Of the 341 cord blood
specimens collected, we harvested > 5.2 mL
serum, the required volume for analyses, in
300 of those specimens. We missed specimen
collections because of complications during
delivery, premature birth and/or small size of
the infant resulting in a small quantity of
available cord blood, and limited staffing.
Infants with missed specimen collection or
insufficient blood volumes, on average, had
shorter gestations and/or lower birth weight
and were more likely to have been ﬁrstborn or
born to younger mothers. Of the 300 speci-
mens available for laboratory analysis, 297
were successfully measured (99%). Without
any knowledge of exposure and outcome sta-
tus, we excluded eight infants, whose moth-
ers’ medical charts reported current or past
thyroid conditions, leaving 289 remaining for
statistical analyses.
Data collection. Two study investigators
abstracted data from maternal medical
records. A 10% random sample was verified
for accuracy by two others. Clinical personnel
obtained cord blood from the umbilical vein
using a syringe prior to the delivery of the pla-
centa; blood samples were processed as previ-
ously described (Herbstman et al. 2007).
Serum samples were analyzed for PBDEs and
PCBs (Sjödin et al. 2004) using an automated
sample handling system (Gilson 215 liquid
handler; Gilson Inc., Middleton, WI) to for-
tify the samples with internal standards and to
carry out protein denaturation and dilution
using formic acid and water, respectively.
Using a Rapid Trace (Caliper Life Sciences,
Hopkinton, MA) modular solid-phase extrac-
tion system, we extracted samples, and coex-
tracted lipids were removed via partitioning
to a silica:silica/sulfuric acid column. We per-
formed the ﬁnal analytic determinations using
gas chromatography isotope dilution high-res-
olution mass spectrometry employing an
MAT95XP instrument (ThermoFinnigan
MAT, Bremen, Germany). We defined the
limit of detection (LOD) in direct relation to
the method blanks and the instrumental
detection limit (Sjödin et al. 2004). In addi-
tion, we measured serum cotinine levels to
verify self-reported smoking status (Bernert
et al. 2000).
Concentrations of TSH, TT4, and FT4
were measured in 300 cord serum samples by
Quest Diagnostics (Baltimore, MD) using the
ADVIA Centaur TSH assay, the Microgenics/
CEDIA TT4 immunoassay, and the Centaur/
Competitive FT4 Chemiluminescent
Immunoassay. 
With institutional review board approvals,
we linked infant records to records in the
Maryland Department of Health and Mental
Hygiene (DHMH) Newborn Screening
Program to obtain results of TT4 measure-
ments from blood spots. All newborns had
blood spots collected before hospital discharge
(on average, at 2 days of age) and analyzed by
radioimmunoassay; measurements from 265
of these infants were available. DHMH rec-
ommends a second T4 test during a routine
pediatric visit; these were collected, on aver-
age, at 18 days of age (range, 5–117 days) for
139 infants in our study.
Data analysis. Statistical analyses used
STATA version 8.0 (StataCorp, College
Station, TX). For PCB and PBDE levels below
the LOD, the value was imputed using the
LOD divided by the square root of 2. PCB and
PBDE levels were lipid-adjusted (nanograms
per gram lipid). Four individual PCB con-
geners—2,3´,4,4´,5-pentaCB (CB-118),
2,2´,3,4,4´,5´-hexaCB/2,3,3´,4,4´,6-hexaCB
(CB-138/CB-158, coelution), 2,2´,4,4´,5,5´-
hexaCB (CB-153), 2,2´,3,4,4´,5,5´-heptaCB
(CB-180)—and three individual PBDE con-
geners—2,2´,4,4´-tetraBDE (BDE-47),
2,2´,4,4´,6-pentaBDE (BDE-100), and
2,2´,4,4´,5,5´-hexaBDE (BDE-153)—were
selected for statistical analysis, based on the pre-
vious epidemiologic investigations (Hagmar
2003; Koopman-Esseboom et al. 1994;
Longnecker et al. 2000; Meeker et al. 2007;
Steuerwald et al. 2000), toxicological evidence
(Darnerud et al. 2007; D’Silva et al. 2004; Safe
1993), and having greater than 60% of samples
with detectable concentrations (Table 1).
Additionally, we used previously proposed
structure- and mechanism-based PCB congener
groupings (Chevrier et al. 2007; Lamb et al.
2006), restricted to PCBs detected in > 75% of
the samples: 2,4,4´,5-tetraCB (CB-74),
2,2´,4,4´,6-pentaCB (CB-99), CB-118, co-
eluting CB-138 and CB-158, and CB-153.
Groupings consisted of PCBs that were mono-
ortho (CB-74 and CB-118) and di-ortho (CB-
99, coeluting CB-138 and CB-158, CB-153,
and CB-180) substituted, and PCBs shown to
induce microsomal enzymes (CB-99, CB-118,
CB-153, and CB-180) (Chevrier et al. 2007). 
We log-transformed PCB, PBDE, and
TSH levels for statistical analyses to satisfy
assumptions of normality. An examination of
the data using lowess curves determined that
the linear models fit the data reasonably.
Therefore, we used univariate and multivariate
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Table 1. Distribution of PCB, PBDE, and thyroid hormone levels in cord blood serum. 
No. Mean ± SD Median Minimum Maximum % < LOD Median LOD
PCBs (ng/g lipid)
CB-74 289 1.7 ± 1.9 1.6 0.6 16.8 21.8 1.1
CB-99 289 2.0 ± 1.9 1.8 0.6 45.0 15.2 1.1
CB-118 289 3.1 ± 1.9 3.0 0.6 97.5 4.5 1.1
CB-138_158 289 5.3 ± 2.1 4.9 0.5 60.2 2.1 1.1
CB-153 289 6.8 ± 2.1 6.3 0.8 72.4 0.4 1.1
CB-180 289 2.9 ± 2.4 2.5 0.5 68.8 10.7 1.1
Mono-ortho 289 4.9 ± 1.9 4.7 1.3 114.3
Di-ortho 289 17.4 ± 2.1 16.0 3.1 176.5
Cyp-inducing 289 15.4 ± 2.0 14.4 3.1 190.9
PBDEs (ng/g lipid)
BDE-47 288 14.4 ± 2.7 13.8 1.1 311.2 9.3 1.3
BDE-100 288 2.5 ± 2.5 2.3 0.5 77.0 35.6 1.2
BDE-153 289 2.8 ± 2.6 2.6 0.6 154.3 39.8 1.3
Thyroid hormones
Cord TSHa (mIU/I) 286 6.68 ± 1.86 6.50 1.30 37.50
Cord TT4 (μg/dL) 287 10.48 ± 2.20 10.50 3.30 17.40
Cord FT4 (ng/dL) 287 1.08 ± 0.16 1.07 0.61 1.70
Hospital blood spotb 265 19.04 ± 5.02 19.24 7.62 37.60
TT4 (μg/dL)
Subsequent blood spotc 139 15.16 ± 3.92 14.80 6.02 25.27
TT4 (μg/dL)
aGeometric mean and geometric SD reported for TSH. bCollected 1.9 ± 0.5 days after birth, on average. cCollected 17.68 ±
16.0 days after birth, on average.linear regression analyses to estimate relation-
ships between the PCBs, PBDEs, and thyroid
hormone measurements. We also used multiple
logistic regression analyses to compare the high-
est quintile (20%) of TSH (high) to the rest of
the distribution (the lower 80%), and the low-
est quintile (20%) of TT4 and FT4 (low) to the
rest of the distribution (the highest 80%). We
evaluated the associations for outliers; excluding
potentially inﬂuential points from the analyses
did not change the inferences. 
We a priori identified gestational age,
maternal age, maternal race, prepregnancy
body mass index (BMI), smoking status, and
number of previous live births as potential con-
founders and included these in all multivariate
models. We derived gestational age from the
best obstetric estimate. We categorized mater-
nal race as white, Asian, or black. We catego-
rized BMI as underweight (BMI < 18.5),
normal (BMI 18.5–24.9), overweight (BMI
25.0–29.9) and obese (BMI ≥ 30.0) (Centers
for Disease Control and Prevention 2005a).
We determined active smoking status using a
combination of recorded smoking during preg-
nancy and/or serum cotinine concentration
> 10.0 ng/mL (Centers for Disease Control
and Prevention 2005b). Parity was coded as
zero versus one or more previous live births.
Additional potential covariates including sex of
the baby; measures of maternal socioeconomic
status; history of sexually transmitted diseases
(STDs), hypertension, diabetes, and anemia;
and the days between delivery and blood spot
collection were evaluated individually using
likelihood ratio tests to determine the best-
ﬁtting models. We examined the ﬁnal multi-
variate models for effect modification by
delivery type (SUVD vs. all other deliveries) by
adding an interaction term to the models. 
Results
The 289 study subjects are described in
Table 2. The median maternal age at birth was
25 years (range, 14–43 years). Approximately
one-third of the mothers did not have a high
school degree, a third completed high school,
and a third had at least 1 year of college. Most
study mothers were black (72%), 21% were
white, and 7% were Asian. Approximately
41% of mothers were delivering their first
child, and 19% were classiﬁed as active smok-
ers during pregnancy. About 48% of mothers
were classiﬁed by their prepregnancy weight as
overweight or obese. A total of 32.5% of the
infants were born by SUVD. About two thirds
of the non-SUVDs were vaginal births with
augmentation or induction, and the rest were
born by cesarean section.
Levels of PCBs, PBDEs, and thyroid hor-
mone levels are presented in Table 1. On
average, TT4 levels rose between birth and the
collection of the hospital blood spots and
then decreased between discharge and the
neonatal measurement. Participants with two
blood spot samples were similar demographi-
cally to those with only one blood spot sam-
ple (data not shown). 
We used linear regression to evaluate the
crude and adjusted relationships between log of
PCB and PBDE concentrations (lipid-adjusted)
and thyroid hormones (see Supplemental
Material, Table 1, online at http://www.
ehponline.org/members/2008/11379/
suppl.pdf). None of these relationships were
statistically significant. Only BDE-100 and
BDE-153 were weakly associated with average
lower TT4 in cord blood. 
None of the PCB congeners or groupings
were associated with the odds of having high
TSH or low TT4 or FT4 in either cord blood
or blood spot measurements (see Supplemental
Material, Table 2, online at http://www.
ehponline.org/members/2008/11379/
suppl.pdf). However, there was some evidence
that PBDEs levels were associated with high
and low thyroid hormone levels. BDE-47 was
associated with reduced odds of having a high
TSH level; BDE-100 was associated with
increased odds of having low cord blood TT4;
and BDE-153 was associated with increased
odds of having low cord blood TT4 and FT4. 
We examined these relationships by deliv-
ery type (SUVD vs. all other deliveries) by
adding an interaction term to the multivariate
models. Because many of the interaction terms
were statistically significant, strata-specific
effects were calculated using linear combina-
tions of regression coefﬁcients from the multi-
variate models. Figure 1 presents the results of
multiple linear regression models of PCB and
PBDE levels and thyroid hormones in cord
blood stratified by type of delivery. Among
babies born by SUVD, higher levels of
CB-118 and CB-180 and the three PBDEs
Herbstman et al.
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Table 2. Distribution of study population characteristics (n = 289).a
Characteristic No. (%)
Maternal age (years)
< 18 25 (8.6)
18–35 244 (84.4)
> 35 20 (6.9)
Race
White 61 (21.1)
Asian 21 (7.3)
Black 207 (71.6)
Education
< High school diploma 86 (30.2)
High school diploma 95 (33.3)
1–4 years college 66 (23.2)
≥ 5 years college 38 (13.3)
BMI (kg/m2)
Underweight (< 18.5) 15 (5.4)
Normal (18.5–24.9) 130 (46.8)
Overweight (25–29.9) 63 (22.7)
Obese (≥ 30) 705 (25.1)
Primiparous
Yes 170 (58.8)
No 119 (41.2)
Smoking status
Active 54 (18.7)
Non/passive smoker 235 (81.3)
Infant sex
Male 160 (55.4)
Female 129 (44.6)
Type of delivery
SUVD 94 (32.5)
All others 195 (67.5)
Gestational age
Preterm 37 (12.8)
Full term 252 (87.2)
Hypertension (preeclampsia, pregnancy induced, and preexisting)
Yes  33 (11.4)
No 256 (88.6)
Diabetes (gestational and preexisting)
Yes 19 (6.6)
No 270 (93.4)
History of STDs
Yes  40 (13.8)
No 249 (86.2)
History of anemia
Yes 37 (12.8)
No 252 (87.2)
aMissing data were excluded from the calculation of percentages. The following data were missing: maternal education
(4) and BMI (11).were associated with lower TSH levels; these
associations were not individually statistically
signiﬁcant (Figure 1A). Among babies born by
SUVD, higher levels of the individual PCBs
and PBDEs were associated with lower TT4
levels. This relationship was statistically signiﬁ-
cant for BDE-100 (Figure 1B). Higher PCB
(but not PBDE) levels were associated with
lower FT4 levels among SUVDs. These associ-
ations were statistically signiﬁcant for CB-118,
CB-153, and CB-180. Conversely, for all
other deliveries, higher levels of PCBs were
associated with higher FT4 levels; these were
statistically signiﬁcant for CB-118 and coelut-
ing CB-138 and CB-158 (Figure 1C). All
three PCB groupings (mono-ortho substituted,
di-ortho substituted, and microsomal
enzyme–inducing PCBs) showed similar rela-
tionships with thyroid hormones as those for
individual PCBs, with significant negative
associations between PCB groupings and FT4
among SUVDs and positive associations
among all other deliveries (data not shown).
Figure 2 displays results of multiple linear
regressions of PCB and PBDE levels and TT4
measured in hospital and neonatal blood
spots stratiﬁed by type of delivery (SUVD vs.
all others). Among “all other” infants, PCB
(but not PBDE) levels were associated with
higher TT4 levels in hospital blood spots.
This relationship is statistically signiﬁcant for
coeluting CB-138 and CB-158 (Figure 2A)
and mono-ortho substituted, di-ortho substi-
tuted, and microsomal enzyme–inducing
PCBs (not shown). Among SUVD infants,
each PCB and PBDE was associated with
lower T4 levels in subsequent blood spots
(Figure 2B). These relationships were statisti-
cally significant for CB-118 and coeluting
CB-138 and CB-158 and the mono-ortho
substituted PCB grouping {2.28 µg/dL
decrease in subsequent TT4 [95% conﬁdence
interval (CI), –4.32 to –0.24] for each 1 nat-
ural log (ln)–adjusted unit change in PCBs}. 
For SUVD infants, the results of multi-
variate logistic regression analyses examining
the relationships between individual PCBs,
PCB groupings, individual PBDEs, and
neonatal thyroid hormones are presented in
Table 3. Infants born by SUVD with higher
levels of each PCB, the PCB groupings, and
each PBDE had a reduced likelihood of hav-
ing high TSH measurements. These results
were statistically significant for BDE-47 and
BDE-100 only. SUVD babies with higher
levels of all PCBs, PCB groups, and PBDEs
were more likely to have a low cord blood
TT4. These relationships were statistically sig-
niﬁcant for all PCB congeners and groupings
and for BDE-100. SUVD babies with higher
levels of PCB congeners and groups and
PBDEs were more likely to have a low cord
blood FT4 levels. These relationships were
statistically signiﬁcant for all of the PCBs and
PCB groupings but not for any of the
PBDEs. Among these babies, each of the
compounds was associated with increased
odds of low T4 levels in the hospital, based on
the blood spot sample; however, none of
these were statistically signiﬁcant. Higher lev-
els of CB-118, coeluting CB-138 and CB-
158, CB-153, the mono-ortho substituted, the
di-ortho substituted, the cyp-inducing PCBs,
and BDE-153 were associated with an
increased likelihood of having a low TT4
measured in the subsequent neonatal blood
spot. These relationships were statistically sig-
nificant at p < 0.05; however, the 95% CIs
for these odds ratios (ORs) are relatively large
as a result of smaller sample sizes in these
stratiﬁed models.
Discussion
In this study, we assessed the relationships
between prenatal exposure to PCBs and
PBDEs and thyroid hormone levels in cord
blood and blood spot samples taken in the
hospital and at neonatal pediatric visits. We
hypothesized that organohalogen exposure
levels would alter thyroid hormone levels, and
speciﬁcally that higher exposures would lower
T4 and raise TSH levels. We found evidence
suggesting that PCB and PBDE may be asso-
ciated with lower TT4 levels in cord blood
and in the subsequent neonatal blood spot
(collected, on average, at 18 days of age).
Overall, umbilical cord levels of PCBs and
PBDEs were not associated with higher TSH
levels or with FT4 levels. 
Before this work, only a small study by
Mazdai et al. (2003) examined the relation-
ship between prenatal PBDE exposure and
thyroid function. In that study, the authors
found no relationship between total PBDEs in
cord blood and cord blood TT4 and FT4
Neonatal PCBs, PBDEs, and thyroid hormone status 
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Figure 2. Change in thyroid hormones measured in blood spots associated with a 1 ln-unit change in analyte
by birth delivery mode. (A) Hospital blood spot TT4 (SUVD = 86; all other deliveries = 179). (B) Subsequent
blood spot TT4 (SUVD = 35; all other deliveries = 104). All models adjusted for baby’s sex, gestational age,
maternal age, maternal race, maternal prepregnancy BMI, smoking status, and time since birth that blood
spot was collected (in days). Error bars represent 95% CIs. 
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Figure 1. Change in cord blood thyroid hormones associated with a 1 ln-unit change in analyte by birth delivery mode. (A) Cord blood TSH (natural log adjusted). In
addition to the covariates above, this model also adjusted for history of STDs and parity. (B) Cord blood TT4. In additional to the covariates above, this model also
adjusted for history of STDs. (C) Cord blood FT4. In addition to the covariates above, this model also adjusted for reported hypertension, diabetes, and anemia.
SUVDs, n = 92 with available data for the multivariate models. All other deliveries, n = 194. All models adjusted for baby’s sex, gestational age, maternal age,
maternal race, maternal prepregnancy BMI, and smoking status. Error bars represent 95% CIs. 
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SUVDs
All other deliveriesamong nine babies, but this study lacked sufﬁ-
cient statistical power (Mazdai et al. 2003).
Several studies have examined the relationship
between prenatal exposure to PCBs and thy-
roid hormone function. Most of these studies
have been reviewed by Hagmar et al. and
Kimbrough and Krouskas (Chevrier et al.
2007; Hagmar 2003; Kimbrough and
Krouskas 2001; Koopman-Esseboom et al.
1994; Longnecker et al. 2000; Matsuura et al.
2001; Ribas-Fito et al. 2003; Steuerwald et al.
2000; Wang et al. 2005). Although the results
have been inconsistent, differences in the
exposure matrices, timing of measures of thy-
roid hormones, PCB congeners measured, and
statistical methods make direct comparisons
difficult. Additionally, none of the previous
studies of prenatal PCB exposure have
addressed the impact of delivery mode on the
relationship between PCBs and thyroid func-
tion, a strong effect modifier in this study.
The recent study by Chevrier et al. (2007)
detected a positive association between TSH
in newborn blood spots and the cyp-inducing
PCBs. We were not able to conﬁrm this ﬁnd-
ing either among all births or among sponta-
neous vaginal unassisted deliveries alone.
However, important differences in study
design may explain these discrepancies. We
did not measure all of the same PCB con-
geners as Chevrier et al. (2007). Additionally,
because neonatal thyroid hormones are
dynamic, the difference in the timing of the
TSH measurement—ours in cord blood at
birth and theirs in bloodspots of newborns
collected a few days after birth—may have
important implications. 
Prior reports have indicated that complica-
tions of labor and delivery can alter thyroid
hormone function in mothers and infants at
the time of delivery (Chan et al. 2001a, 2003).
Several studies have demonstrated associations
between mode of delivery and measures of
stress-related hormones measured in maternal
and umbilical cord blood (Gitau et al. 2001;
Mears et al. 2004; Vogl et al. 2006). In
response to stress, the production of hormones
including epinephrine, norepinephrine, and
cortisol is increased. These increases alter the
hypothalamic–pituitary–adrenal axis, which is
also involved in thyroid hormone production
(Charmandari et al. 2005). Although we had
no direct measure of intrapartum stress, the
medical charts clearly indicated the delivery
mode (i.e., vaginal or cesarean section),
whether labor was spontaneous or aug-
mented, and whether the delivery required
assistance or intervention (i.e., forceps, vac-
uum, etc.). We had hypothesized a priori,
based on the published literature, that sponta-
neous, unassisted, and vaginal deliveries
would be less likely to involve intrapartum
stress than other deliveries [augmented vagi-
nal deliveries and emergency (nonelective)
cesarean deliveries]; hence, we expected that
relationships between PCBs, PBDEs, and
thyroid hormone levels might be more easily
detectable among such births (Chan et al.
2001a, 2001b; Lao and Lee 2002; Miyamoto
et al. 1991). However, the extent of effect
modiﬁcation we observed was unexpected. 
The biologic mechanism explaining the
difference in effect between the spontaneous
vaginal deliveries and other deliveries is
unknown. Delivery stress is associated with
elevated cord TSH levels (Lao and Panesar
1989; Tehrani et al. 2003). Possibly, the
increased TSH triggers the production of T4.
Alternatively, elevated TSH levels may be a
response to low circulating T4 among babies
with delivery-induced stress. In either case, if
vaginal deliveries requiring augmentation and
cesarean sections after attempted labor are
stressful for the infant, this may initiate a cas-
cade of hormonal responses that may mask
subtle thyroid perturbations in association
with prenatal PCB and/or PBDE levels. We
explored the possibility of analyzing infants
delivered by elective cesarean as a separate
group that would be expected to have very lit-
tle stress as a result of delivery, but there are
only 26 elective cesarean sections in this popu-
lation—too few for analyses. Moreover, these
elective cesarean sections include mothers and
babies with preexisting medical conditions
that also may be associated with stress. 
In this study, the observed relationships
between PCB and PBDE serum levels and
specific thyroid hormone measures generally
were consistently in the same direction, even
when they were not individually statistically
significant. Such consistency of association
supports the hypothesis that there are true
associations between prenatal PCB and
PBDE exposure and thyroid hormone levels.
Alternatively, this consistency may be attrib-
utable to positive correlations among PCB
and PBDE congeners. However, PCB levels
are not correlated with PBDE levels in this
population (Herbstman et al. 2007). Given
the large number of individual models, the
consistency of associations across the individ-
ual PCB and PBDE congeners and PCB
groupings is reassuring.
It is difﬁcult to extrapolate between associ-
ations at the lower exposure levels observed in
this population and the much higher levels
observed in animal studies. The difference in
exposure levels may elicit different effects,
given the possibility of nonmonotonic
dose–response relationships that have been
observed previously for endocrine effects (Rice
and Barone 2000). Despite compelling evi-
dence from animal models, it is possible that
humans and animals respond differently to
these organohalogen exposures (Kimbrough
and Krouskas 2001). For example, it has been
suggested that the principal thyroid transport
protein in humans is T4-binding globulin
compared with transthyretin, which is the
main thyroid hormone transporter in rodents
(Cheek et al. 1999; Kimbrough and Krouskas
2001). Therefore, if PCBs and/or PBDEs are
competitively binding with the transthyretin
protein in rodents, the pattern of responses for
humans could be different. 
Several prior epidemiology studies also
have reported on populations with thyroid
hormone levels within the clinically normal
range (Koopman-Esseboom et al. 1994;
Longnecker et al. 2000; Matsuura et al. 2001;
Herbstman et al.
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Table 3. Adjusted ORs (95% CIs) for thyroid hormone levels in response to organohalogen exposure among babies born by SUVD, n = 92.a
Hospital blood spot Subsequent blood spot
ln TSHb (mIU/I) TT4
c (μg/dL) FT4
d (ng/dL) T4 (μg/dL) T4 (μg/dL)e
Highf vs. lowest 80% Lowg vs. highest 80% Low vs. highest 80% Low vs. highest 80% Low vs. highest 80%
PCB-118 0.35 (0.12–1.05) 2.91 (1.17–7.20)* 4.20 (1.51–11.71)* 1.99 (0.72–5.50) 4.53 (1.53–13.41)*
PCB-138_158 0.53 (0.22–1.27) 2.44 (1.08–5.48)* 2.47 (1.01–6.00)* 1.07 (0.44–2.64) 5.30 (1.73–16.21)*
PCB-153 0.52 (0.20–1.33) 2.37 (1.05–5.33)* 3.51 (1.39–8.82)* 1.32 (0.50–3.51) 3.40 (1.31–8.83)*
PCB-180 0.43 (0.18–1.03) 2.22 (1.06–4.64)* 2.19 (1.00–4.80)* 1.35 (0.56–3.24) 1.89 (0.83–4.30)
Mono-ortho 0.44 (0.14–1.40) 3.02 (1.18–7.69)* 4.17 (1.47–11.82)* 2.10 (0.72–6.10) 5.01 (1.64–15.26)*
Di-ortho 0.46 (0.17–1.26) 2.62 (1.13–6.04)* 3.15 (1.24–7.95)* 1.30 (0.48–3.57) 3.80 (1.40–10.33)*
Cyp-inducers 0.43 (0.12–1.22) 2.70 (1.14–6.38)* 3.52 (1.34–9.22)* 1.56 (0.56–4.41) 3.58 (1.32–9.71)*
BDE-47 0.39 (0.19–0.78)* 1.46 (0.82–2.59) 1.79 (0.94–3.40) 1.64 (0.83–3.24) 1.28 (0.65–2.54)
BDE-100 0.36 (0.16–0.82)* 2.14 (1.10–4.18)* 1.69 (0.84–3.40) 2.01 (0.95–4.28) 2.08 (0.93–4.69)
BDE-153 0.56 (0.26–1.17) 1.30 (0.71–2.39) 1.59 (0.81–3.10) 1.28 (0.61–2.67) 2.25 (1.07–4.75)*
aAll models adjusted for baby’s sex, gestational age, maternal age, maternal race, maternal prepregnancy BMI, smoking status. bTSH also adjusted for history of STDs and parity. cTT4
also adjusted for history of STDs. dFT4 also adjusted for reported hypertension, diabetes, and anemia. eBoth blood spot measurements were also adjusted for time since birth blood spot
was collected (in days). fHigh: being in the highest quintile. gLow: being in the lowest quintile. *Models where the 95% CIs around the OR do not include 1.0.Ribas-Fito et al. 2003; Steuerwald et al. 2000;
Wang et al. 2005). Comparison of dose
among epidemiology studies is also challeng-
ing. For PCB levels, a study by Hagmar pro-
posed a relative body burden (RBB) measure
for comparing studies with different analytic
methods, different congeners measured, dif-
ferent biological matrices, and with and with-
out adjustment for lipid composition
(Hagmar 2003). By this method, the geomet-
ric mean total RBB for PCBs in this study is
26.9 ng/g lipid compared with 1,120 ng/g
lipid reported in the Faroese population
(Steuerwald et al. 2000). Steuerwald et al.
observed that higher total PCBs were weakly
associated with lower TSH levels, perhaps
consistent with our ﬁndings, even though our
RBB levels were much lower. 
Timing of exposure in early development
likely is critical. It would be interesting to
assess thyroid hormone expression earlier in
pregnancy and before the timing of the devel-
opment of an intact hypothalamic–pituitary
axis, which can compensate for small pertur-
bations. It may be possible to investigate this
hypothesis by studying hormone levels in
amniotic ﬂuid, which was not available in this
study population. We were able to assess thy-
roid hormone levels at three points in time
(birth, approximately 2 days after delivery,
and at a subsequent time, generally within
1 month). In our study, among babies born
via SUVD, both PCBs and PBDEs were asso-
ciated with TT4 at all three time points.
However, the associations were more consis-
tently statistically significant in the cord T4
and subsequent blood spot measurement.
This may be caused partly by the dynamic
nature of T4 levels during the ﬁrst few days of
life after the TSH surge at birth (Büyükgebiz
2006). It also provides evidence that the effect
of PCBs on thyroid status, detectable among
babies born by SUVD, may persist. Timing
of blood spot collection was measured in
units of days. It is likely that a more refined
measurement of this important covariate
might have captured its inﬂuence on thyroid
hormone measurements more completely.
The subsequent blood spot measurement was
not available for a significant fraction of the
samples in our study, somewhat limiting the
inferences that can be made. Other studies
have examined the impact of prenatal PCB
exposure weeks, months, and sometimes years
after birth. For example, Koopman-Esseboom
et al. (1994) found that CB-118, CB-138,
CB-153, and CB-180 measured in cord
blood were positively associated with TSH
levels at 2 weeks of age. This may be consis-
tent with our finding in that the later blood
spot was collected in babies who are about the
same age (average, 18 days), although we
observed low T4 rather than increased TSH,
which was not measured. 
There is also the possibility that other
unmeasured factors may affect the relation-
ship between PCBs, PBDEs, and thyroid
function. For example, we did not measure
iodine status in this population. Iodine is
known to be related to thyroid hormone syn-
thesis and regulation and may also be related
to PCB and PBDE exposure through the diet,
because both iodine and PCBs may be found
in ﬁsh (Boyages 1993). 
Despite the limitations of this study, we
saw patterns indicating that among babies
born by SUVD, PCBs are associated with
lower TT4 levels at all three time points and
with FT4 levels in cord blood. Weaker evi-
dence suggests a similar relationship between
PBDEs and TT4 in cord blood. These differ-
ences indicate that despite apparent structural
similarities between PCBs and PBDEs, these
chemicals may be eliciting different endocrine
effects in humans or that PBDEs are less
potent than PCBs in this regard. Future stud-
ies may want to investigate this relationship
more thoroughly, because it is clear that even
small perturbations in thyroid hormone levels
at critical exposure windows may have long-
lasting health impacts (Branchi et al. 2003). 
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